Public health surveillance of cancer survival in the United States and worldwide: The contribution of the CONCORD programme : Public Health Surveillance of Cancer Survival
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d5053045e66">CONCORD is a programme for the global surveillance
of cancer survival. In 2015, the
second cycle of the program (CONCORD-2) established long-term surveillance of cancer
survival worldwide, for the first time, in the largest cancer survival study published
to date. CONCORD-2 provided cancer survival trends for 25,676,887 patients diagnosed
during the 15-year period between 1995 and 2009 with 1 of 10 common cancers that collectively
represented 63% of the global cancer burden in 2009. Herein, the authors summarize
the past, describe the present, and outline the future of the CONCORD programme. They
discuss the difference between population-based studies and clinical trials, and review
the importance of international comparisons of population-based cancer survival. This
study will focus on the United States. The authors explain why population-based survival
estimates are crucial for driving effective cancer control strategies to reduce the
wide and persistent disparities in cancer survival between white and black patients,
which are likely to be attributable to differences in access to early diagnosis and
optimal treatment. Cancer 2017;123:4977-81. Published 2017. This article is a U.S.
Government work and is in the public domain in the USA.
</p>